Cytos Biotechnology Ltd will participate at South Europe &
Switzerland Midcap Event in Paris, France
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Dr. Wolfgang A. Renner, CEO of Cytos Biotechnology Ltd will attendand meet investors at the South Europe & Switzerland Midcap Event onThursday, October 22, 2009 in Paris, France.Cytos Biotechnology Ltd is a public Swiss biotechnology company thatspecializes in the discovery, development and commercialization of anew class of biopharmaceutical products - the Immunodrugs(TM).Immunodrugs(TM) are intended for use in the treatment and preventionof common chronic diseases, which afflict millions of peopleworldwide. Immunodrugs(TM) are designed to instruct the patient'simmune system to produce desired therapeutic antibody or T cellresponses that modulate chronic disease processes. Taking advantageof the high flexibility of its Immunodrug(TM) platform, CytosBiotechnology has built a diversified pipeline of Immunodrug(TM)candidates in various disease areas, of which six are currently inclinical development. The Immunodrug(TM) candidates are developedboth in-house and together with Novartis, Pfizer and Pfizer AnimalHealth. Founded in 1995 as a spinoff from the Swiss Federal Instituteof Technology (ETH) in Zurich, the Company is located in Schlieren(Zurich). Currently, the Company has 86 full-time employees. CytosBiotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).For further information please contact:Patricia KochCorporate CommunicationsAssistant Executive BoardCytos Biotechnology LtdPhone: +41 44 733 47 03Fax: +41 44 733 47 04e-Mail: patricia.koch(at)cytos.comWebsite: www.cytos.com --- End of Message ---Cytos Biotechnology AGWagistrasse 25 Zurich-Schlieren Switzerland WKN: 804352; ISIN: CH0011025217; Index: SPIEX, SPI, Swiss All Share Index;Listed: Main Market in SIX Swiss Exchange;
Datum: 20.10.2009 - 17:45 Uhr
Sprache: Deutsch
News-ID 7154
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 390 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytos Biotechnology Ltd will participate at South Europe &
Switzerland Midcap Event in Paris, France"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
